PSTI.TA - Pluristem Therapeutics Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
182.40
-7.60 (-4.00%)
As of 11:04AM IDT. Market open.
Stock chart is not supported by your current browser
Previous Close190.00
Open182.00
Bid182.10 x 32000
Ask183.00 x 849800
Day's Range180.00 - 195.00
52 Week Range180.00 - 596.00
Volume361,415
Avg. Volume309,520
Market Cap261.987M
Beta (3Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-0.25
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire17 days ago

    Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million

    Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates,  announced today the pricing of an underwritten public offering of 27,142,858 shares of its common stock and warrants to purchase up to 27,142,858 shares of its common stock with an exercise price of $0.70 per share at a public offering price of $0.70 per share and accompanying warrant. The warrants in the underwritten public offering have a term of five years and are exercisable immediately upon issuance. Pluristem also announced the pricing of a concurrent registered direct offering of 1,428,571 shares of its common stock at a price of $0.70 per share.

  • Benzinga17 days ago

    The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 3) Denali Therapeutics Inc (NASDAQ: DNLI ) GALAPAGOS NV/S ...

  • GlobeNewswire17 days ago

    Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock

    Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today that it intends to offer and sell shares of its common stock and warrants in an underwritten public offering and shares of its common stock in a concurrent registered direct offering. All of the shares and warrants in the underwritten public offering, and the shares in the concurrent registered direct offering, are to be sold by Pluristem. Pluristem intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or warrants offered in the public offering at the public offering price, less the underwriting discounts and commissions.

  • GlobeNewswirelast month

    Pluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company has fully enrolled the second cohort of six patients in its ongoing Phase I clinical study evaluating PLX-R18 for the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT), and has received Data and Safety Monitoring Board (DSMB) approval to continue to the final cohort of the study. “We are highly encouraged by the findings from the first two cohorts in this study, and we are pleased to receive DSMB approval to continue with the study as planned, as we look to efficiently advance PLX-R18 through clinical development,” commented Zami Aberman, Chairman and Co-Chief Executive Officer of Pluristem.

  • GlobeNewswire2 months ago

    Pluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced a collaboration between the company and NASA’s Ames Research Center to evaluate the potential of Pluristem’s PLX cell therapies in preventing and treating medical conditions caused during space missions. Dr. Ruth Globus of NASA’s Ames Research Center, in California’s Silicon Valley, has been awarded a 2019 NASA Ames Research Innovation Award (ARIA) for the collaboration with Pluristem.

  • GlobeNewswire2 months ago

    RESTORE Consortium, of which Pluristem is a member, Nominated to Be One of Two Finalists Competing for a Potential Award for Development of Advanced Therapeutics

    Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, today announced that the large-scale research initiative, RESTORE, of which Pluristem is a member, is nominated to be one of two finalists competing to be awarded up to €1 billion over the next 10 years by the EC for the development and advancement of transformative therapeutics. As a member of the RESTORE consortium, if RESTORE wins the award, Pluristem could receive a portion of the award, the amount of which is not yet determinable.

  • Associated Press2 months ago

    Pluristem: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Haifa, Israel-based company said it had a loss of 7 cents. The biotechnology company posted revenue of $50,000 in the period. In the final minutes of trading on Wednesday, the ...

  • GlobeNewswire3 months ago

    Pluristem to Collaborate with Israeli Ministry of Defense in the Treatment of Burn Injuries

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported the receipt of a joint grant awarded by the Israeli Ministry of Defense and the Israel Innovation Authority for the development of the company’s PLX cells for the treatment of burn injuries. This project entails collaboration between the Company, the Israeli Defense Forces (IDF) medical corps and professionals who specialize in burn injuries from Israeli hospitals.

  • GlobeNewswire3 months ago

    Pluristem Therapeutics Reports Successful Case Study in Treatment of Buerger’s Disease Patient

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative-medicine company developing novel placenta-based cell therapy products, today reported a successful one-year follow up of a compassionate use treatment in a Buerger’s disease patient treated with Pluristem’s PLX-PAD. The thirty-six years old patient, who was diagnosed with Buerger’s disease approximately four years ago, displayed painful, non-healing ulcers on his foot.

  • GlobeNewswire4 months ago

    Pluristem Concludes Positive Meeting with FDA on Development Plan for Acute Radiation Syndrome

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced it has concluded a positive meeting with the U.S. Food and Drug Administration (FDA) regarding the ongoing development of PLX-R18 for the treatment of Acute Radiation Syndrome (ARS). The FDA provided Pluristem with feedback on the progress and data collected on PLX-R18 to date and gave guidance towards advancing the development of PLX-R18 with respect to the treatment of ARS.

  • GlobeNewswire4 months ago

    Pluristem Therapeutics Recaps Key Opinion Leader Meeting on Peripheral Artery Disease (PAD)

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today provided a recap of the Key Opinion Leader (KOL) breakfast meeting on peripheral artery disease (PAD) that the Company hosted on Friday, December 14 in New York. The meeting focused on the current treatment landscape, unmet medical need, economic impact and potential market opportunities for treating patients with PAD, a serious but common circulatory problem characterize by a blockage of the arteries and reduced blood flow to the limbs.

  • GlobeNewswire4 months ago

    Reminder- Pluristem Therapeutics to Host Key Opinion Leader Meeting on Peripheral Artery Disease Tomorrow

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, will host a Key Opinion Leader (KOL) meeting on Peripheral Artery Disease (PAD) tomorrow, December 14, 2018 at 8am-9:30am EST, in New York City. The meeting will feature presentations by KOLs John Lantis, MD, Vice Chairman of the Department of Surgery and Chief of Vascular and Endovascular Surgery at Mount Sinai West, and Mary L. Yost, MBA, Co-Founder of The Sage Group, who will discuss the current treatment landscape and unmet medical needs, the economic impact, and potential market opportunities for treating patients with PAD.

  • GlobeNewswire5 months ago

    Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has entered into a license agreement with a subsidiary of Chart Industries, Inc. regarding Pluristem’s thawing device for cell-based therapies. Pluristem’s point-of-care thawing device technology is designed to allow for the precise and automated thawing of cells in a controlled and monitored environment, and is expected to result in the highest levels of cell viability and quality. The technology includes many advanced unique proprietary features which were designed to result in the leading thawing devices on the market.

  • GlobeNewswire5 months ago

    Pluristem Presents Data from First Cohort in Ongoing Phase I Hematological Study at the American Society of Hematology (ASH) Annual Meeting

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company presented data from the first cohort of patients in its ongoing Phase I clinical trial of PLX-R18 for the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT) at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, which is being held December 1-4 in San Diego.

  • GlobeNewswire5 months ago

    Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at American Society of Hematology’s (ASH) Annual Meeting

    A Phase I study of PLX-R18 cells to treat incomplete hematopoietic recovery following HCT is ongoing in U.S. and Israel. The trial is designed as a multi-center, open-label, dose-escalating study to evaluate the safety of intramuscular injections (IM) of PLX-R18 cells in 24 subjects with incomplete hematopoietic recovery persisting for at least 4 months after HCT.

  • GlobeNewswire5 months ago

    New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company presented additional data from its Phase II clinical study evaluating PLX-PAD for the treatment of Intermittent Claudication (IC) at the 2018 American Heart Association Scientific Sessions in Chicago. The data were presented by Prof. Norbert Weiss, MD, Director of the Vascular Center at the Technical University of Dresden, Germany, and the lead European Principal Investigator for the Phase II IC study.

  • Associated Press5 months ago

    Pluristem: Fiscal 1Q Earnings Snapshot

    The Haifa, Israel-based company said it had a loss of 8 cents per share. The biotechnology company posted revenue of $4,000 in the period. The company's shares closed at $1.18. A year ago, they were trading ...

  • GlobeNewswire5 months ago

    Pluristem Therapeutics Reports Fiscal 2019 First Quarter Results and Provides Corporate Update

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported financial results for its fiscal first quarter 2019 ended September 30, 2018 and provided a corporate update. “We were very pleased to announce this quarter on FDA approval of an expanded access program that will provide critical limb ischemia patients who are not suitable for enrollment in our Phase III trial with access to PLX-PAD while the trial is ongoing,” said Yaky Yanay, Co-Chief Executive Officer and President of Pluristem. “During the fiscal first quarter and subsequent period, we continued to make progress advancing our pipeline of novel placenta-based cell therapy products in multiple indications.” Mr. Yanay continued, "We are making good progress in enrolling patients in both ongoing Phase III clinical trials of PLX-PAD in critical limb ischemia (CLI) and the treatment of muscle injury following hip fracture.

  • What does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Balance Sheet Tell Us About Its Future?
    Simply Wall St.7 months ago

    What does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Balance Sheet Tell Us About Its Future?

    Pluristem Therapeutics Inc (NASDAQ:PSTI), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PSTIRead More...